IMMUNOLOGY2026™ Conference Recordings For Attendees-Prime-Target neoantigen vaccination strategy enhances neoantigen-specific T cell immunity at the tumor microenvironment in murine cold tumor models

Prime-Target neoantigen vaccination strategy enhances neoantigen-specific T cell immunity at the tumor microenvironment in murine cold tumor models

Back to course

Video Transcription

Video Summary

The speaker presented a “prime-and-target” neoantigen vaccination strategy for cold, immunosuppressive tumors. In this approach, subcutaneous vaccination primes neoantigen-specific T cells systemically, while intratumoral vaccination with the same neoantigens plus adjuvants recruits those T cells into the tumor. Although subcutaneous vaccination alone induced strong T-cell responses in the spleen, it did not control tumors because T cells remained excluded from the tumor microenvironment. The combined strategy promoted tumor infiltration by Th1 and effector CD4/CD8 T cells, reduced Tregs and M2-like macrophages, increased T-cell recruiting chemokines and interferons, and caused necrotic tumor ulceration and strong tumor regression. The method worked in multiple cold tumor models and achieved complete rejection in many mice. Single-cell analyses showed expanded T-cell clones and a shift toward an anti-tumor immune state.

Meta Tag

Date April 16, 2026 11:00 AM - 11:15 AM

Room 157

Session Novel Tumor Therapies

Speaker Kou Hioki

Track Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

Year 2026

Keywords

neoantigen vaccination

prime-and-target strategy

cold tumors

T-cell infiltration

tumor regression

April 16, 2026 11:00 AM - 11:15 AM

157

Novel Tumor Therapies

Kou Hioki

Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

2026